Response's NT-proBNP CHF (congestive heart failure) test:
This article was originally published in Clinica
Canadian regulators have given Response Biomedical approval to market its test for the congestive heart failure (CHF) marker NT-proBNP. The test, which is run of the firm's portable RAMP platform, is designed to help diagnose and assess severity in individuals suspected of having CHF, and may aid in the risk stratification of patients with acute coronary syndrome and heart failure. The British Columbia, Canada-based firm is one of several companies that markets a CHF test based on NT-proBNP or its biologically-active counterpart, BNP. RAMP NT-proBNP is already available in Europe and is pending US FDA clearance.